Trailing the Big Pharma players, a lesser known BCMA CAR-T candidate comes into the spotlight
Nanjing, China., April 09, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with the title 'Fully Human BCMA targeted chimeric Antigen Receptor T Cells for Relapse/Refractory Multiple Myeloma' at Global Summit on Hematologic Malignancies in Urayasu, Japan on April 20-21.
